Learn more about Lundbeck's mid- to late-stage development program (phase 1 projects are not included)
Research is our foundation
Lundbeck is the only fully-integrated pharmaceutical company in the world, solely devoted to the treatment of psychiatric and neurological disorders. We dedicate our entire R&D efforts to develop innovative drugs for treatment of a number of psychiatric and neurological disorders. Our R&D projects focus on:
Underlying disease biology
Lundbeck’s R&D strategy is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of psychiatric and neurological disorders. This approach allows us to treat the symptoms more effectively and also to potentially alter the course of the diseases. The strategy required comprehensive research into the brain and the biology and mechanisms of psychiatric and neurological disorders, as well as improved understanding of research targets and clinical outcomes.
Essential to the R&D strategy is for Lundbeck to maintain strong internal R&D capabilities in order to establish optimal networks and opportunities. We will continue to build external alliances to supplement our internal capabilities, taking advantage of the increased opportunities provided by innovative technologies. Our structure allows us to run an extensive co-development on pipeline projects, particularly in our alliances with Takeda Pharmaceutical Co., Limited and Otsuka Pharmaceutical Co., Ltd. The structure enables Lundbeck to have more development projects running in tandem, whilst being able to invest considerably more than what is directly available from our R&D resources.
Our R&D strategy will provide a future platform from which Lundbeck can discover and develop drugs with clearly documented effects on biologically defined patient groups. It is expected that society’s demand for this new type of drugs will increase.
Our R&D organization
As a medium-sized pharmaceutical company, we share common values in the way we work worldwide and keep a clear focus in our R&D strategy. Research at Lundbeck is based on the efforts of our multi-disciplinary, empowered project teams, our in-house expertise in the psychiatric and neurological disorders area and our state-of-the-art technologies. We work in new, well-equipped laboratories. In each project team, we integrate our advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.
Our R&D organization is international and consists of more than 800 dedicated R&D staff. The research organization is located in Copenhagen, Denmark. Development headquarters are situated in Copenhagen, Denmark with clinical research and regulatory personnel spread worldwide.
Respect for the individual
At Lundbeck R&D, we work together as individuals towards common goals. We seek to constantly develop and improve our scientific and personal skills and qualifications. This allows us to promote career opportunities for the individual, as well as maintain and develop our competencies as an organization. Publication of our scientific results is a natural part of our participation as active members in the international scientific community.
Development of a new pharmaceutical product
No. of molecules / No. of patients